About
Throughout my career, I have been driven by scientific discovery and the identification…
Articles by Peter
-
Profiles in Scientific Courage: The First Cancer Cures
Profiles in Scientific Courage: The First Cancer Cures
By Peter Lebowitz
-
Courage & Conviction in Scientific Discovery
Courage & Conviction in Scientific Discovery
By Peter Lebowitz
Activity
-
An excellent coach or mentor can be a game-changer in both life and business. Do you have one? - **Guidance and Experience**: A good mentor…
An excellent coach or mentor can be a game-changer in both life and business. Do you have one? - **Guidance and Experience**: A good mentor…
Liked by Peter Lebowitz
-
Congrats Mahadi and Rybrevant team! These results are truly remarkable.
Congrats Mahadi and Rybrevant team! These results are truly remarkable.
Shared by Peter Lebowitz
-
Most comedians love a bit of casual sexism But watch this video Because it's so rare that you will see a comedian take the stage And use his…
Most comedians love a bit of casual sexism But watch this video Because it's so rare that you will see a comedian take the stage And use his…
Liked by Peter Lebowitz
Experience
Education
Licenses & Certifications
-
Internal Medicine and Medical Oncology
Medical License (District of Columbia - active)
Patents
-
Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Issued USPTO 08952018
See patentA novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the…
A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer.
More activity by Peter
-
Very happy to join the Neomorph board and support a fantastic team driving towards innovative medicines.
Very happy to join the Neomorph board and support a fantastic team driving towards innovative medicines.
Shared by Peter Lebowitz
-
Congratulations to the Rybrevant team. This program is an amazing example of world class innovation in discovery and development driven by an…
Congratulations to the Rybrevant team. This program is an amazing example of world class innovation in discovery and development driven by an…
Shared by Peter Lebowitz
-
The R-Tank® Underground Stormwater Module provides a versatile option for green infrastructure applications. The high void ratio and modular…
The R-Tank® Underground Stormwater Module provides a versatile option for green infrastructure applications. The high void ratio and modular…
Liked by Peter Lebowitz
-
After an intense week of science, networking, and fun, 2024 Drug Carriers Gordon Conference came to a close, and I am now finally a “Past GRC Chair”.…
After an intense week of science, networking, and fun, 2024 Drug Carriers Gordon Conference came to a close, and I am now finally a “Past GRC Chair”.…
Liked by Peter Lebowitz
-
WOW .."Say it to my face"-Kamala Michigan: Harris +11 Arizona: Harris +2 Nevada: Harris +2 Wisconsin: Harris +2 Georgia: Tied #Kamalaharris…
WOW .."Say it to my face"-Kamala Michigan: Harris +11 Arizona: Harris +2 Nevada: Harris +2 Wisconsin: Harris +2 Georgia: Tied #Kamalaharris…
Liked by Peter Lebowitz
-
Really appreciated the engaging conversation with Kyle LaHucik at Endpoints News and his reporting on Third Arc’s Series A launch yesterday. Thank…
Really appreciated the engaging conversation with Kyle LaHucik at Endpoints News and his reporting on Third Arc’s Series A launch yesterday. Thank…
Shared by Peter Lebowitz
-
Today marks a significant milestone in the next chapter (or arc) of my career. After retiring from J&J as the Global Head of Oncology R&D in January,…
Today marks a significant milestone in the next chapter (or arc) of my career. After retiring from J&J as the Global Head of Oncology R&D in January,…
Shared by Peter Lebowitz
-
Such an honor to be inducted this evening as Senior Member of National Academy of Inventors Proud to be at Brown University an NAI member…
Such an honor to be inducted this evening as Senior Member of National Academy of Inventors Proud to be at Brown University an NAI member…
Liked by Peter Lebowitz
-
As a new lawyer, I was trained to write emails to opposing counsel as if the email would be an exhibit read by the judge. It’s a helpful check on…
As a new lawyer, I was trained to write emails to opposing counsel as if the email would be an exhibit read by the judge. It’s a helpful check on…
Liked by Peter Lebowitz
-
See Full Prescribing Info including Boxed Warning: https://e.lilly/zepboundPI A pen designed with the patient in mind.
See Full Prescribing Info including Boxed Warning: https://e.lilly/zepboundPI A pen designed with the patient in mind.
Liked by Peter Lebowitz
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More